Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 11/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828839 | 1.00 | ADRA2A (0.54) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| Hydrochloric Acid SCHEMBL6456272 | 0.99 | ADRA2A (0.53) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| SCHEMBL6463409 | 0.89 | ADRA2A (0.46) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| SCHEMBL6463406 | 0.89 | ADRA2A (0.46) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| Hydrochloric Acid SCHEMBL6464588 | 0.88 | ADRA2A (0.46) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| SCHEMBL13793992 | 0.81 | NPY5R (0.63) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| Hydrochloric Acid SCHEMBL3942791 | 0.81 | NPY5R (0.62) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| Hydrochloric Acid SCHEMBL3942793 | 0.81 | NPY5R (0.62) | ADRA2AMCHR1NPY5RPRKCQEPHX2 | |
| SCHEMBL13793960 | 0.79 | MCHR1 (0.82) | ADRA2AMCHR1NPY5R | |
| Hydrochloric Acid SCHEMBL3946437 | 0.78 | MCHR1 (0.81) | ADRA2AMCHR1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | ADRA2A 117/4885MCHR1 2/4885NPY5R 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.